National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Rivaroxaban 10mg/day plus a P2Y12 inhibitor for stroke prevention due to NVAF in patients with renal impairment undergoing PCI with stent placement.

 

NCPE Assessment Process Complete
Rapid review commissioned 20/11/2017
Rapid review completed 21/11/2017
Rapid Review outcome Full pharmacoeconomic assessment recommended

The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.